364 related articles for article (PubMed ID: 32751679)
1. Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.
Marin JJG; Perez-Silva L; Macias RIR; Asensio M; Peleteiro-Vigil A; Sanchez-Martin A; Cives-Losada C; Sanchon-Sanchez P; Sanchez De Blas B; Herraez E; Briz O; Lozano E
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751679
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Resistance to Chemotherapy in Gastric Cancer.
Marin JJ; Al-Abdulla R; Lozano E; Briz O; Bujanda L; Banales JM; Macias RI
Anticancer Agents Med Chem; 2016; 16(3):318-34. PubMed ID: 26234359
[TBL] [Abstract][Full Text] [Related]
3. Molecular Bases of Chemoresistance in Cholangiocarcinoma.
Marin JJG; Lozano E; Briz O; Al-Abdulla R; Serrano MA; Macias RIR
Curr Drug Targets; 2017; 18(8):889-900. PubMed ID: 25706108
[TBL] [Abstract][Full Text] [Related]
4. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.
Marin JJG; Macias RIR; Monte MJ; Romero MR; Asensio M; Sanchez-Martin A; Cives-Losada C; Temprano AG; Espinosa-Escudero R; Reviejo M; Bohorquez LH; Briz O
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585893
[TBL] [Abstract][Full Text] [Related]
5. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.
Marin JJ; Monte MJ; Blazquez AG; Macias RI; Serrano MA; Briz O
Acta Pharmacol Sin; 2014 Jan; 35(1):1-10. PubMed ID: 24317012
[TBL] [Abstract][Full Text] [Related]
6. Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.
Marin JJG; Macias RIR; Monte MJ; Herraez E; Peleteiro-Vigil A; Blas BS; Sanchon-Sanchez P; Temprano AG; Espinosa-Escudero RA; Lozano E; Briz O; Romero MR
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32933095
[TBL] [Abstract][Full Text] [Related]
7. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.
Marin JJG; Monte MJ; Macias RIR; Romero MR; Herraez E; Asensio M; Ortiz-Rivero S; Cives-Losada C; Di Giacomo S; Gonzalez-Gallego J; Mauriz JL; Efferth T; Briz O
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884584
[TBL] [Abstract][Full Text] [Related]
8. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.
Marin JJ; Briz O; Monte MJ; Blazquez AG; Macias RI
Curr Cancer Drug Targets; 2012 May; 12(4):402-38. PubMed ID: 22229248
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells.
Hamzehlou S; Momeny M; Zandi Z; Kashani B; Yousefi H; Dehpour AR; Tavakkoly-Bazzaz J; Ghaffari SH
Eur J Pharmacol; 2019 Nov; 863():172705. PubMed ID: 31574259
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters.
Al-Abdulla R; Perez-Silva L; Lozano E; Macias RIR; Herraez E; Abad M; Segues N; Bujanda L; Briz O; Marin JJG
Biochem Pharmacol; 2020 Jan; 171():113682. PubMed ID: 31669256
[TBL] [Abstract][Full Text] [Related]
12. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
13. Models for Understanding Resistance to Chemotherapy in Liver Cancer.
Marin JJG; Herraez E; Lozano E; Macias RIR; Briz O
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671735
[TBL] [Abstract][Full Text] [Related]
14. Molecular bases of the poor response of liver cancer to chemotherapy.
Marin JJG; Briz O; Herraez E; Lozano E; Asensio M; Di Giacomo S; Romero MR; Osorio-Padilla LM; Santos-Llamas AI; Serrano MA; Armengol C; Efferth T; Macias RIR
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):182-192. PubMed ID: 29544679
[TBL] [Abstract][Full Text] [Related]
15. Molecular bases of liver cancer refractoriness to pharmacological treatment.
Marin JJ; Romero MR; Briz O
Curr Med Chem; 2010; 17(8):709-40. PubMed ID: 20088759
[TBL] [Abstract][Full Text] [Related]
16. Cancer Chemoresistance; Recent Challenges and Future Considerations.
Adil M; Kanwal S; Rasheed S; Iqbal M; Abbas G
Cancer Treat Res; 2023; 185():237-253. PubMed ID: 37306912
[TBL] [Abstract][Full Text] [Related]
17. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
18. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
19. Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia.
Marin JJ; Briz O; Rodríguez-Macias G; Díez-Martín JL; Macias RI
Blood Rev; 2016 Jan; 30(1):55-64. PubMed ID: 26321049
[TBL] [Abstract][Full Text] [Related]
20. Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours.
Marin JJ; Romero MR; Martinez-Becerra P; Herraez E; Briz O
Curr Mol Med; 2009 Dec; 9(9):1108-29. PubMed ID: 19747110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
